Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noam Barda

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Nature Medicine|September 8, 2021
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancyNoa Dagan, Noam Barda, Tal Biron-Shental, et al.
Circulation. Cardiovascular Interventions|November 6, 2024
Enhancing Coronary Revascularization Decisions: The Promising Role of Large Language Models as a Decision-Support Tool for Multidisciplinary Heart TeamKarin Sudri, Iris Motro-Feingold, Roni Ramon-Gonen, et al.
Emerging Infectious Diseases|April 26, 2024
SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023Yaniv Lustig, Michal Canetti, Victoria Indenbaum, et al.
Nature Communications|September 8, 2020
Developing a COVID-19 mortality risk prediction model when individual-level data are not availableNoam Barda, Dan Riesel, Amichay Akriv, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2022
The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 InfectionNoam Barda, Michal Canetti, Mayan Gilboa, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|July 29, 2022
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022Limor Kliker, Neta Zuckerman, Nofar Atari, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2022
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022Noam Barda, Michal Canetti, Mayan Gilboa, et al.
Viruses|January 8, 2025
Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort StudyGili Joseph, Ili Margalit, Yael Weiss-Ottolenghi, et al.
The New England Journal of Medicine|June 29, 2022
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of AgeChandra J Cohen-Stavi, Ori Magen, Noam Barda, et al.
Nature Communications|December 13, 2022
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti, Noam Barda, Mayan Gilboa, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Nature Medicine|September 8, 2021
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancyNoa Dagan, Noam Barda, Tal Biron-Shental, et al.
Circulation. Cardiovascular Interventions|November 6, 2024
Enhancing Coronary Revascularization Decisions: The Promising Role of Large Language Models as a Decision-Support Tool for Multidisciplinary Heart TeamKarin Sudri, Iris Motro-Feingold, Roni Ramon-Gonen, et al.
Emerging Infectious Diseases|April 26, 2024
SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023Yaniv Lustig, Michal Canetti, Victoria Indenbaum, et al.
Nature Communications|September 8, 2020
Developing a COVID-19 mortality risk prediction model when individual-level data are not availableNoam Barda, Dan Riesel, Amichay Akriv, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2022
The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 InfectionNoam Barda, Michal Canetti, Mayan Gilboa, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|July 29, 2022
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022Limor Kliker, Neta Zuckerman, Nofar Atari, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 30, 2022
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022Noam Barda, Michal Canetti, Mayan Gilboa, et al.
Viruses|January 8, 2025
Persistence of Long COVID Symptoms Two Years After SARS-CoV-2 Infection: A Prospective Longitudinal Cohort StudyGili Joseph, Ili Margalit, Yael Weiss-Ottolenghi, et al.
The New England Journal of Medicine|June 29, 2022
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of AgeChandra J Cohen-Stavi, Ori Magen, Noam Barda, et al.
Nature Communications|December 13, 2022
Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-upMichal Canetti, Noam Barda, Mayan Gilboa, et al.
Pageof 6